Physician profile
Maria C Motta
NPI 1649819350
$22,969.97
in general payments reported to CMS, 2019-2025
26 companies · $21K in 2025
The $21K reported for 2025 was more than what 99% of Gerontology (Nurse Practitioner) providers received nationally (typical 2025 total: $180).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $220 · 2022: $96.31 · 2023: $1,072 · 2024: $464 · 2025: $21K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $10K · Travel and Lodging: $6,070 · Consulting Fee: $2,880 · Food and Beverage: $2,389 · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $679 · Education: $273.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $10,362.50 |
| Travel and Lodging | $6,069.88 |
| Consulting Fee | $2,880.00 |
| Food and Beverage | $2,389.20 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $679.35 |
| Education | $272.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Syndax Pharmaceuticals, INC. | $13,214.27 | 2025 | Revuforj |
| Amgen INC. | $6,217.58 | 2021-2025 | Blincyto, Blincyto |
| Astrazeneca Pharmaceuticals Lp | $726.50 | 2024-2025 | Calquence |
| Pfizer INC. | $723.45 | 2023 | |
| Taiho Oncology, INC. | $425.37 | 2025 | |
| Incyte Corporation | $262.66 | 2021-2025 | Niktimvo, Jakafi |
| Stemline Therapeutics INC. | $196.71 | 2025 | Elzonris |
| Celgene Corporation | $174.35 | 2021-2025 | Reblozyl |
| Astellas Pharma US INC | $173.99 | 2023-2025 | |
| Sobi, INC | $156.45 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $121.82 | 2023 | Reblozyl |
| Daiichi Sankyo INC. | $92.37 | 2024-2025 | Vanflyta |
| Genzyme Corporation | $73.33 | 2022-2023 | |
| Takeda Pharmaceuticals U.S.A., INC. | $64.11 | 2021-2024 | Iclusig |
| Abbvie INC. | $62.74 | 2021-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genentech USA, INC. | $56.94 | 2024 | Venclexta |
| Jazz Pharmaceuticals INC. | $39.29 | 2025 | |
| Glaxosmithkline, LLC. | $29.99 | 2025 | Ojjaara, Blenrep |
| Pharmacyclics LLC, An Abbvie Company | $29.30 | 2021 | |
| Alexion Pharmaceuticals, INC. | $23.20 | 2022 | |
| Janssen Biotech, INC. | $22.35 | 2021 | |
| Rigel Pharmaceuticals, INC. | $19.34 | 2025 | Tavalisse, Rezlidhia, Gavreto |
| Eisai INC. | $18.43 | 2025 | |
| Merck Sharp & Dohme LLC | $17.05 | 2023 | Dificid, Prevymis |
| Seagen INC. | $15.03 | 2022 | |
| Emd Serono, INC. | $13.35 | 2023 | Bavencio |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Motta listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.